PD-1 x VEGF antibodies show potential to surpass checkpoint inhibitors as standard-of-care in multiple oncology indications NAYA aiming to initiate clinical trials in early 2026 SARASOTA, Fla. and MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and women’s health,... Read More

SARASOTA, Fla. and MIAMI, Oct. 31, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced that it is presenting novel insights into the mode of action of its GPC3-targeting NK engager bispecific antibody NY-303 to support phase I/IIa clinical trials in H1 2025... Read More

SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced an update regarding its clinic trial plans. The Company received regulatory approval from the Israeli Ministry of Health in July 2024 and subsequent institutional review... Read More

SARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) -- INVO Biosciences (Nasdaq: INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology, and autoimmune diseases through the merger of INVO Biosciences and NAYA Biosciences, today confirmed it has changed its corporate name to NAYA Biosciences Inc. and will begin trading under the new symbol “NAYA” at the market... Read More

SARASOTA, Fla. and MIAMI, Oct. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience (“INVO”) (NASDAQ: INVO) today announced it has closed its merger with NAYA Biosciences , a company dedicated to increasing patient access to breakthrough treatments in oncology and autoimmune diseases. The combined company expects to change its name to NAYA Biosciences and trade on the NASDAQ under the “NAYA” ticker. The combined company will... Read More

SARASOTA, Fla., Aug. 14, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell ® medical device, today announced financial results for the second quarter 2024 for... Read More

SARASOTA, Fla., May 15, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the first quarter of... Read More

SARASOTA, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide through the establishment and acquisition of fertility clinics, and with the intravaginal culture ("IVC") procedure enabled by its INVOcell® medical device, today announced financial results for the fourth quarter... Read More

NAYA to accelerate Phase II clinical development and Early Patient Access after initial safety demonstrated in 28-patient clinical trial Program developed by Florida Biotechnologies, Inc. & the University of Miami’s Bascom Palmer Eye Institute NAYA continuing to implement acquisition roll-up of clinical and commercial assets in oncology, regenerative medicine, and fertility NAYA expects to close its previously announced... Read More

INVO (NASDAQ: INVO ) and NAYA Biosciences expect to close their previously announced merger in the first quarter of 2024 Experienced, entrepreneurial leadership team to help structure merged public company and accelerate growth SARASOTA, Fla. and AVENTURA, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience , a healthcare services company focused on expanding access to advanced fertility treatment worldwide, which has... Read More

Abstract from 2023 American Society of Hematology (ASH) Meeting Data demonstrates differentiated profile from DARZALEX® (daratumumab) with best-in-class potential, supports initiation of clinical trials in 2024 NAYA expects to close its previously announced merger with INVO Bioscience (NASDAQ: INVO ) in the first quarter of 2024 AVENTURA, Fla. and SARASOTA, Fla. , Dec. 11, 2023 /PRNewswire/ -- NAYA Biosciences Inc. ("NAYA"),... Read More

NAYA Biosciences and ONK Therapeutics to assess proof-of-concept and establish activity and feasibility of the combination of NAYA's FLEX-NK™ bispecific antibodies and ONK's optimally engineered natural killer (NK) cells for the treatment of cancer Partnership may be expanded to joint clinical development following successful completion of the initial research Combination therapy expected to improve response rate and address... Read More

SARASOTA, Fla. , Nov. 28, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the Company received notice from The Nasdaq Capital Market, LLC ("Nasdaq"), dated November 22, 2023 ,... Read More

Company Expects to Host Conference Call Shortly After November 20, 2023 Following the Progress of Certain Closing Conditions Pertaining to the Announced Merger Agreement with NAYA Biosciences SARASOTA, Fla. , Nov. 13, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell®... Read More

SARASOTA , Fla. and AVENTURA, Fla. , Nov. 10, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide, and NAYA Biosciences Inc. ("NAYA"), a company dedicated to increasing patient access to breakthrough treatments in oncology and regenerative medicine, today jointly announced that following the closing of their... Read More

SARASOTA, Fla. , Nov. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services company focused on expanding access to advanced fertility treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure it enables, announced that it is soliciting waivers (the " Waiver Solicitation ") from holders of the Company's common stock purchase... Read More

An Introduction to NAYA Biosciences with CEO Dr. Daniel Teper Managing unprecedented medical innovation in an era of financial market volatility Increasing patient access to breakthrough treatments in oncology, regenerative medicine, and fertility SARASOTA, Fla. and AVENTURA, Fla. , Oct. 27, 2023 /PRNewswire/ -- INVO... Read More

Post-merger, the combined company, operating under the name "NAYA Biosciences", will be dedicated to increasing patient access to life-transforming treatments in oncology, fertility, and regenerative medicine NAYA will seek to scale up profitable revenues in the fertility segment, enter into revenue-generating pharma partnerships for its therapeutic programs, and strategically develop and acquire synergistic technologies and... Read More

SARASOTA, Fla. , Oct. 11, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, announced today that Steve Shum , CEO, will be participating in a Panel Presentation at the Lytham Partners Fall 2023... Read More

SARASOTA, Fla. , Sept. 29, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company") today announced that its special meeting of shareholders on September 29, 2023 (the "Special Meeting") was convened and then adjourned, without conducting any business, in order to provide shareholders additional time within which to vote on the proposals as described in the Company's definitive proxy statement... Read More

SARASOTA, Fla. , Sept. 28, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure it enables, reminds its shareholders to vote ahead of the upcoming special meeting of shareholders (the "Special Meeting") to be held... Read More

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla. , Aug. 14, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the second quarter ended June 30,... Read More

Transformational and accretive acquisition adds significant scale to INVO's current operations Contributes over $5 million in incremental annual revenue as well as positive net income and cash flows First significant transaction establishing acquisitions as key aspect of INVO's commercial strategy, in addition to building new INVO Centers SARASOTA, Fla. and MADISON, Wis. , Aug. 11, 2023 /PRNewswire/ -- INVO Bioscience, Inc.... Read More

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , Aug. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its second quarter... Read More

SARASOTA, Fla. , Aug. 8, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the closing of its public offering of 1,580,000 units, with each unit consisting of one share of common stock... Read More

SARASOTA, Fla. , Aug. 4, 2023 /PRNewswire/ -- INVO Bioscience, Inc. ( Nasdaq:INVO) ("INVO" or the "Company"), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the pricing of its public offering of 1,580,000 units, with each unit consisting of one share of common stock... Read More

Company sets closing date deadline of acquisition to August 10, 2023 -- Acquisition is expected to significantly enhance total annual revenue and contribute positive net income to the company's operating results Transition to healthcare services company allows INVO to accelerate IVC volume, allowing for a greater share in total fertility cycle revenue Targeting cash flow breakeven in 2024 SARASOTA, Fla. , Aug. 3, 2023... Read More

SARASOTA, Fla. , July 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, announced today that it will effect a 1-for-20 reverse split of its issued and outstanding and authorized common stock... Read More

INVOcell now cleared for 5-day incubation period Supporting data reflects improved patient outcomes, similar to IVF SARASOTA, Fla. , June 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today... Read More

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla. , May 15, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the quarter ended March 31, 2023 and... Read More

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , May 8, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a commercial-stage fertility company focused on expanding access to advanced infertility treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its first... Read More

Company to Host Conference Call Today at 4:30pm ET SARASOTA, Fla. , April 17, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced financial results for the fourth quarter and fiscal year... Read More

Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla. , April 11, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO) , a commercial-stage fertility company focused on expanding access to advanced infertility treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure it enables, will report financial results for its... Read More

INVO recently announced the signing of binding agreements to acquire this top-rated clinic SARASOTA, Fla. and MADISON, Wis. , April 5, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced infertility treatment worldwide... Read More

SARASOTA, Fla. , March 30, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced preliminary financial results for the fourth quarter and year ended December 31, 2022 . The Company expects... Read More

SARASOTA, Fla. , March 27, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure it enables, today announced the closing of its previously announced registered direct offering of 3,680,000 shares of common stock (or... Read More

SARASOTA, Fla. , March 24, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell ® medical device and the intravaginal culture ("IVC") procedure it enables, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional... Read More

Accretive acquisition expected to add significant scale to INVO's operations Contributes over $5 million in incremental annual revenue as well as positive net income Initial transaction that establishes acquisitions as 3 rd key aspect of INVO's commercial strategy, in addition to building new INVO Centers and partnering with existing IVF clinics SARASOTA, Fla. and MADISON, Wis. , March 20, 2023 /PRNewswire/ -- INVO... Read More

SARASOTA, Fla. , Jan. 5, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (Nasdaq: INVO) ("INVO" or the "Company"), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture ("IVC") procedure it enables, today announced it has entered an exclusive distribution agreement with Ming Mei Technology Co. Ltd ("Ming Mei") for Taiwan.... Read More

Shelly W. Holmström, M.D. FACOG, to serve as physician operator at soon to be opened Tampa -based INVO Center. The current metro area population of Tampa in 2022 is 2,945,000. INVO Centers focus on serving patients in need of advanced fertility care utilizing the efficient, effective, and affordable INVOcell ® solution.... Read More

Patient was part of a prospective peer reviewed study of INVOcell compared to conventional IVF (cIVF) in Malaysia INVOcell provides an advanced, effective and affordable infertility treatment option to help increase access to care. The multi-billion-dollar global fertility market is predicted to reach approximately US$47.9 billion by 2030 yet remains severely underserved with many patients unable to access affordable... Read More